دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
Johanna Holmgren, MD, Anna Fröborg, MD, Isabella Visuri, MD, Jonas Halfvarson, MD, PhD, Henrik Hjortswang, MD, PhD, Pontus Karling, MD, PhD, Pär Myrelid, MD, PhD, Ola Olén, MD, PhD, The SWIBREG study group , Jonas F Ludvigsson, MD, PhD, Olof Grip, MD, PhD
doi : 10.1093/ibd/izac097
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 339–348
Serious infections have been observed in patients with inflammatory bowel disease (IBD) on anti-TNF use—but to what extent these infections are due to anti-TNF or the disease activity per se is hard to disentangle. We aimed to describe how the rates of serious infections change over time both before and after starting anti-TNF in IBD.
Integrating Radiomics With Clinicoradiological Scoring Can Predict High-Risk Patients Who Need Surgery in Crohn’s Disease: A Pilot Study
Prathyush Chirra, MS, Anamay Sharma, MD, Kaustav Bera, MD, H Matthew Cohn, MD, Jacob A Kurowski, MD, Katelin Amann, BS, Marco-Jose Rivero, MD, Anant Madabhushi, PhD, Cheng Lu, PhD, Rajmohan Paspulati, MD, Sharon L Stein, MD, Jeffrey A Katz, MD, Satish E Viswanath, PhD, Maneesh Dave, MD, MPH
doi : 10.1093/ibd/izac211
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 349–358
Early identification of Crohn’s disease (CD) patients at risk for complications could enable targeted surgical referral, but routine magnetic resonance enterography (MRE) has not been definitively correlated with need for surgery.
Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission
Kousaku Kawashima, MD, PhD, Naoki Oshima, MD, PhD, Kenichi Kishimoto, MD, Masatoshi Kataoka, MD, Mai Fukunaga, MD, Satoshi Kotani, MD, Hiroki Sonoyama, MD, PhD, Akihiko Oka, MD, PhD, Yoshiyuki Mishima, MD, PhD, Hideaki Kazumori, MD, PhD, Noriyoshi Ishikawa, MD, PhD, Asuka Araki, MD, PhD, Shunji Ishihara, MD, PhD
doi : 10.1093/ibd/izac095
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 359–366
Consensus regarding the cutoff value of fecal calprotectin (FC) for predicting histological healing (HH) in ulcerative colitis (UC) is lacking. This study aimed to determine an optimal FC cutoff value for predicting HH in patients with UC with clinical and endoscopic remission. Furthermore, FC’s predictability for prolonged clinical remission (CR) was investigated.
Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn’s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Mohammad Shehab, MD, FRCPC, Fatema Alrashed, PharmD, BCPS, Valérie Heron, MD, FRCPC, Sophie Restellini, MD, Talat Bessissow, MD, FRCPC
doi : 10.1093/ibd/izac103
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 367–375,
The medical treatment of fistulizing Crohn’s disease (CD) remains a challenge to clinicians. Over the last 20 years, biologic therapies have been the mainstay of medical treatment of fistulizing CD. The purpose of this study is to compare the efficacy of biologic therapies in inducing response and remission in fistulizing CD.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Antonio Tursi, MD, Giammarco Mocci, MD, PhD, Leonardo Allegretta, MD, Giovanni Aragona, MD, Maria Antonia Bianco, MD, Raffaele Colucci, MD, Antonio Cuomo, MD, PhD, Nicola Della Valle, MD, PhD, Antonio Ferronato, MD, Giacomo Forti, MD, Federica Gaiani, MD, PhD, GianMarco Giorgetti, MD, Maria Giovanna Graziani, MD, Katia Lofano, MD, Roberto Lorenzetti, MD, Tiziana Larussa, MD, PhD, Antonio Penna, MD, Roberta Pica, MD, Giuseppe Pranzo, MD, Stefano Rodino’, MD, Antonella Scarcelli, MD, Costantino Zampaletta, MD, Gabrio Bassotti, MD, PhD, Alessia Immacolata Cazzato, MD, Stefania Chiri, MD, Valeria Clemente, MD, Andrea Cocco, MD, Gianluigi de’ Angelis, MD, Laura Donnarumma, MD, Roberto Faggiani, MD, Camilla Graziosi, MD, Marco Le Grazie, MD, Francesco Luzza, MD, PhD, Costantino Meucci, MD, Rita Monterubbianesi, MD, Cristiano Pagnini, MD, Patrizia Perazzo, MD, Marcello Picchio, MD, Rodolfo Sacco, MD, PhD, Ladislava Sebkova, MD, Mariaelena Serio, MD, Daniele Napolitano, RN, Daniela Pugliese, MD, PhD, Franco Scaldaferri, MD, PhD, Elisa Schiavoni, RN, Laura Turchini, RN, Alessandro Armuzzi, MD, PhD, Walter Elisei, MD, PhD, Giovanni Maconi, MD, Alfredo Papa, MD, PhD
doi : 10.1093/ibd/izac092
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 376–383
Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the originator. However, comparative data on the efficacy and safety of the various ADA biosimilars remains scarce.
Inflammatory Bowel Disease and Long-term Risk of Cancer: A Prospective Cohort Study Among Half a Million Adults in UK Biobank
Shanshan Wu, PhD, Sian Xie, PhD, Changzheng Yuan, ScD, Zhirong Yang, PhD, Si Liu, PhD, Qian Zhang, PhD, Feng Sun, PhD, Jing Wu, PhD, Siyan Zhan, PhD, Shengtao Zhu, PhD, Shutian Zhang, PhD
doi : 10.1093/ibd/izac096
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 384–395
This study aims to examine the prospective association of inflammatory bowel disease (IBD) with long-term risk of overall, site-specific cancer and cancer-specific mortality in middle-aged and older people.
The Impact of Periodontitis on Inflammatory Bowel Disease Activity
Gorm Roager Madsen, MD, Kristina Bertl, PhD, Nikolaos Pandis, DDS, MS, Andreas Stavropoulos, DDS, PhD, Johan Burisch, MD, PhD
doi : 10.1093/ibd/izac090
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 396–404
Inflammatory bowel disease (IBD) and periodontitis are chronic, progressive, inflammatory diseases with similarly complex pathogeneses that involve an interplay between dysbiotic microbiota and dysregulated immune-inflammatory responses.
Multimodal Brain MRI of Deep Gray Matter Changes Associated With Inflammatory Bowel Disease
Bradley G Goodyear, PhD, Faranak Heidari, MSc, Richard J M Ingram, MD, PhD, Filomeno Cortese, MSc, Nastaran Sharifi, MD, Gilaad G Kaplan, MD, MPH, Christopher Ma, MD, MPH, Remo Panaccione, MD, Keith A Sharkey, PhD, Mark G Swain, MD, MSc
doi : 10.1093/ibd/izac089
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 405–416
Behavioral symptoms, including mood disorders, substantially impact the quality of life of patients with inflammatory bowel disease (IBD), even when clinical remission is achieved.
Long-Term Outcomes of the Excluded Rectum in Crohn’s Disease: A Multicenter International Study
Gassan Kassim, MD, Clara Yzet, MD, Nilendra Nair, PhD, Anketse Debebe, PhD, Alexa Rendon, MS, Jean-Frédéric Colombel, MD, Cindy Traboulsi, MD, David T Rubin, MD, Annalisa Maroli, PhD, Elisabetta Coppola, MS, Michele M Carvello, MD, Nadat Ben David, MD, Francesca De Lucia, MD, PhD, Matteo Sacchi, MD, Silvio Danese, MD, PhD, Antonino Spinelli, MD, PhD, Meike M C Hirdes, PhD, Joren ten Hove, MD, Bas Oldenburg, MD, PhD, Aurada Cholapranee, MD, Maxine Riter, BS, Dana Lukin, MD, Ellen Scherl, MD, Esen Eren, MD, MS, Keith S Sultan, MD, Jordan Axelrad, MD, MPH, David B Sachar, MD
doi : 10.1093/ibd/izac099
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 417–422,
Many patients with Crohn’s disease (CD) require fecal diversion. To understand the long-term outcomes, we performed a multicenter review of the experience with retained excluded rectums.
High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course
Stephanie L Gold, MD, Loren G Rabinowitz, MD, Laura Manning, MPH, RDN, CDN, Laurie Keefer, PhD, William Rivera-Carrero, MD, Stephanie Stanley,, MS, Alexis Sherman, RN, Ana Castillo, RN, Stacy Tse, PharmD, Amanda Hyne,, MSW, Kristina Matos,, MSW, Benjamin Cohen, MD, Ari Grinspan, MD, Jean-Frederic Colombel, MD, Bruce E Sands, MD, MS, Marla C Dubinsky, MD, Ryan C Ungaro, MD, MS
doi : 10.1093/ibd/izac102
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 423–429
Patients with inflammatory bowel disease (IBD) are at an increased risk of malnutrition. The goal of this study was to define the prevalence of malnutrition and micronutrient deficiencies in recently diagnosed IBD patients and to compare the performance of existing malnutrition screening tools in identifying IBD patients at increased risk for malnutrition.
Vaccination Against Measles, Mumps, Rubella and Incident Inflammatory Bowel Disease in a National Cohort of Privately Insured Children
Catherine Kim, MD, MPH, Zhe Yin, MAS, Neil Kamdar, MA, Ryan Stidham, MD
doi : 10.1093/ibd/izac176
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 430–436
Infection is believed to be a potential trigger for inflammatory bowel disease (IBD). Whether vaccination against childhood infections including measles, mumps, and rubella may reduce risk of IBD is uncertain.
Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype
Bethany Choi, BSc, Michael Sey, MD, Terry Ponich, MD, Melanie Beaton, MD, Richard Kim, MD, Aze Wilson, MD, PhD
doi : 10.1093/ibd/izac188
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 437–443
Multiple variables contribute to variation in patient exposure and response to tumor necrosis factor alpha antagonist biologics such as infliximab.
Colonic Epithelial Circadian Disruption Worsens Dextran Sulfate Sodium–Induced Colitis
Sarah B Jochum, MD, Phillip A Engen, MS, Maliha Shaikh, MS, Ankur Naqib, PhD, Sherry Wilber, Shohreh Raeisi, MS, Lijuan Zhang, MD, Shiwen Song, MD, Gabriella Sanzo, BA, Vijit Chouhan, MD, Frank Ko, PhD, Zoe Post, MD, Laura Tran, BS, Vivian Ramirez, MS, Stefan J Green, PhD, Khashayarsha Khazaie, PhD, Dana M Hayden, MD, MPH, Mark J Brown, PhD, Robin M Voigt, PhD, Christopher B Forsyth, PhD, Ali Keshavarzian, MD, Garth R Swanson, MD, MS
doi : 10.1093/ibd/izac219
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 444–457
Disruption of central circadian rhythms likely mediated by changes in microbiota and a decrease in gut-derived metabolites like short chain fatty acids (SCFAs) negatively impacts colonic barrier homeostasis.
Medical and Surgical Implications of Mesenteric Adipose Tissue in Crohn’s Disease: A Review of the Literature
Phillip Gu, MD, Shishir Dube, PhD, Dermot P B McGovern, MD, PhD
doi : 10.1093/ibd/izac120
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 458–469
Mesenteric adipose tissue (MAT) has gained substantial attention as an active player in Crohn’s disease (CD), but its clinical significance is poorly understood and likely reflects, in part, difficulties assessing MAT noninvasively
Mycobiome and Inflammatory Bowel Disease: Role in Disease Pathogenesis, Current Approaches and Novel Nutritional-based Therapies
Caitlyn Hsu, HSDG, Mahmoud Ghannoum, PhD, Fabio Cominelli, MD, PhD, Luca Di Martino
doi : 10.1093/ibd/izac156
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 470–479
Inflammatory bowel disease (IBD), a disorder characterized by chronic inflammation of the gastrointestinal (GI) tract and a range of adverse health effects including diarrhea, abdominal pain, vomiting, and bloody stools, affects nearly 3.1 million genetically susceptible adults in the United States today.
Surgical Management of Enterovesical Fistula in Crohn’s Disease in the Biologic Era
Nicholas P McKenna, MD, Scott R Kelley, MD, Katherine A Bews, BA, Kevin T Behm, MD, Kellie L Mathis, MD
doi : 10.1093/ibd/izac133
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 480–482
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Kimberly N Weaver, MD, Xian Zhang, PhD, Xiangfeng Dai, PhD, Wenli Chen, MS, MA, Runa Watkins, MD, Jeremy Adler, MD, MSc, Marla C Dubinsky, MD, Arthur Kastl, MD, Athos Bousvaros, MD, MPH, Jennifer A Strople, MD, Raymond K Cross, MD, MS, Peter D R Higgins, MD, PhD, MSc, Ryan C Ungaro, MD, MS, Meenakshi Bewtra, MD, PhD, MPH, Emanuelle Bellaguarda, MD, Francis A Farraye, MD, MS, Riley Craig, BS, Cristian Hernandez, BS, Margie E Boccieri, MA, Ann Firestine, MS, Kelly Y Chun, PhD, Millie D Long, MD, MPH, Michael D Kappelman, MD, MPH
doi : 10.1093/ibd/izac138
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 483–486
Micronutrients and Their Role in Inflammatory Bowel Disease: Function, Assessment, Supplementation, and Impact on Clinical Outcomes Including Muscle Health
Stephanie L Gold, MD, Laura Manning, RD, David Kohler, BA, Ryan Ungaro, MD, MS, Bruce Sands, MD, MS, Maitreyi Raman, MD, MSc
doi : 10.1093/ibd/izac223
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 487–501
Helicobacter pylori and Inflammatory Bowel Disease: An Unresolved Enigma
Juris Pokrotnieks, MD, PhD, Stanislav Sitkin, MD, PhD
doi : 10.1093/ibd/izac248
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages e5–e6
Patients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccination: Correspondence
Rujittika Mungmunpuntipantip, PhD, Viroj Wiwanitkit, MD
doi : 10.1093/ibd/izac257
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023,
Reply to “Patients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccination�
Hiep Phan, MD, Mary S Hayney, PharmD, MPH, Freddy Caldera, DO, MS
doi : 10.1093/ibd/izad006
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages e8–e9,
Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases
Sem Geertsema, MD, Antonius T Otten, MD, Dianne G Bouwknegt, MD, Marijn C Visschedijk, MD, PhD, Arno R Bourgonje, MD
doi : 10.1093/ibd/izac265
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages e10–e11
Fecal Mucin O-Glycans as Novel Biomarkers in Inflammatory Bowel Diseases
Catherine Robbe Masselot, PhD, Camille Cordier, Pharm D, Benjamin Marsac, MS, Maria Nachury, MD, Renaud Léonard, PhD, Boualem Sendid, Pharm D, PhD
doi : 10.1093/ibd/izac282
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Page e12
